The firm will assess irpagratinib plus best supportive care in patients with FGF19-overexpressing advanced liver cancer.

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.

The firm is developing the PHOX2B-targeted cell therapy, which has shown promise in preclinical xenograft models, with CHOP researchers.

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

Medical ethicists are bringing attention to an early chapter of precision medicine history, an often overlooked aspect of an ...

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

NEW YORK – Ionis Pharmaceuticals has treated the first patient in a Phase III clinical trial evaluating the efficacy and safety of its investigational antisense oligonucleotide (ASO) therapy for ...

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...